ONO 4819
Alternative Names: ONO 4819CDLatest Information Update: 26 May 2006
At a glance
- Originator Ono Pharmaceutical
- Class Heptanoic acids; Osteoporosis therapies
- Mechanism of Action Dinoprostone agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Fracture
Most Recent Events
- 31 Mar 2006 Discontinued - Phase-II for Fracture treatment in Japan (Injection)
- 31 Mar 2002 Phase-II clinical trials in Fracture treatment in Japan (Injection)
- 14 Nov 2001 Phase-I clinical trials for Fracture treatment in Japan (Unknown route)